Enliven CFO exercises options and sells 6,018 shares

Enliven Therapeutics, Inc. chief financial officer Benjamin Hohl exercised stock options and sold shares of common stock in coordinated transactions.

Rhea-AI Filing Summary

Enliven Therapeutics, Inc. chief financial officer Benjamin Hohl exercised stock options and sold shares of common stock in coordinated transactions. He exercised options for 6,018 shares at an exercise price of $2.48 per share and then sold 6,018 shares in several open-market trades on June 17, 2026 at weighted average prices between $42.79 and $44.75 per share. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan. Following the transactions, Hohl directly holds 51,000 shares of Enliven common stock, indicating he retains a meaningful equity stake in the company.

Insights

Equity compensation and insider-trading analyst

CFO exercised options and sold matching shares under a 10b5-1 plan.

Benjamin Hohl, CFO of Enliven Therapeutics, exercised options for 6,018 shares of common stock at an exercise price of $2.48 per share and sold 6,018 shares in open-market transactions on June 17, 2026. The sale prices were reported as weighted averages in the low- to mid-$40s.

The filing states that both the option exercise and related sales were conducted under a Rule 10b5-1 trading plan adopted on March 18, 2026, indicating the trades were pre-scheduled rather than opportunistic. After these transactions, Hohl directly holds 51,000 shares of common stock, so the activity appears to be a routine liquidity and compensation event with a continuing ownership position.

Insider Trade Summary 10b5-1

Exercise and Sale: 6,018 shares ($249K approx. pre-tax spread)

Exercise and Sale 5 txns

Insider Hohl Benjamin

Role CHIEF FINANCIAL OFFICER

Sold 6,018 shs ($264K)

Approx. gross sale proceeds $264K

Approx. exercise cost $15K

Approx. pre-tax spread $249K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	6,018	$0.00	$0.00
Exercise	Common Stock	6,018	$2.48	$15K
Sale	Common Stock	1,379	$42.785	$59K
Sale	Common Stock	3,401	$43.8634	$149K
Sale	Common Stock	1,238	$44.7475	$55K

Holdings After Transaction: Stock Option (right to buy) — 86,038 contracts (Direct); Common Stock — 51,000 shares (Direct)

Footnotes (6)

1. F1. The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026.
2. F2. Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
3. F3. This transaction was executed in multiple trades at prices ranging from $42.295 to $43.27. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
4. F4. This transaction was executed in multiple trades at prices ranging from $43.3342 to $44.3142. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
5. F5. This transaction was executed in multiple trades at prices ranging from $44.3548 to $44.945. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
6. F6. All of the shares subject to this option are fully vested and exercisable as of the date hereof.

Key Figures

Shares sold: 6,018 shares Sale prices: $42.79–$44.75 per share Options exercised: 6,018 shares at $2.48/share +1 more

4 metrics

Shares sold 6,018 shares Open-market sales on June 17, 2026

Sale prices $42.79–$44.75 per share Weighted average prices for three sale tranches

Options exercised 6,018 shares at $2.48/share Stock option exercise on June 17, 2026

Post-transaction holdings 51,000 shares Common stock directly held after transactions

Key Terms

Rule 10b5-1 trading plan, restricted stock units (RSUs), weighted average sale price, Stock Option (right to buy)

4 terms

Rule 10b5-1 trading plan regulatory

"effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

restricted stock units (RSUs) financial

"Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share"

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

weighted average sale price financial

"The price reported above reflects the weighted average sale price."

Stock Option (right to buy) financial

"Stock Option (right to buy) ... All of the shares subject to this option are fully vested and exercisable"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Enliven Therapeutics (ELVN) CFO Benjamin Hohl do in this Form 4?

CFO Benjamin Hohl exercised stock options for 6,018 Enliven shares at $2.48 and sold 6,018 shares in open-market trades. All transactions occurred on June 17, 2026 and were reported as part of his equity compensation activity.

How many Enliven Therapeutics (ELVN) shares did the CFO sell and at what prices?

The CFO sold 6,018 Enliven common shares in three open-market transactions. Weighted average sale prices were about $42.79, $43.86, and $44.75 per share, with each line item reflecting multiple trades within narrow price ranges that are detailed in the footnotes.

How many Enliven Therapeutics (ELVN) shares does the CFO own after these transactions?

After the reported option exercise and sales, CFO Benjamin Hohl directly holds 51,000 Enliven common shares. This figure reflects his position following the June 17, 2026 activity and indicates he maintains a continuing equity stake in the company.

Were the Enliven Therapeutics (ELVN) insider trades under a Rule 10b5-1 plan?

Yes. The filing states the option exercise and related sales were executed under a Rule 10b5-1 trading plan adopted by the reporting person on March 18, 2026. Such plans pre-schedule trades, reducing the significance of short-term market timing.

What stock options did the Enliven Therapeutics (ELVN) CFO exercise in this Form 4?

He exercised a stock option covering 6,018 shares of Enliven common stock at a conversion or exercise price of $2.48 per share. A footnote notes all shares subject to this option were fully vested and exercisable as of the transaction date.

Does the Enliven Therapeutics (ELVN) Form 4 mention restricted stock units (RSUs)?

Yes. A footnote notes that certain securities are restricted stock units, each RSU representing a contingent right to receive one Enliven common share. These RSUs are subject to specific vesting schedules and conditions before shares are actually delivered.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/22/2026 - 05:13 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hohl Benjamin

(Last) (First) (Middle)

C/O ENLIVEN THERAPEUTICS, INC.

205 PARK ROAD

(Street)

BURLINGAME CALIFORNIA 94010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Enliven Therapeutics, Inc. [ ELVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/17/2026		M(1)		6,018	A	$2.48	57,018(2)	D
Common Stock	06/17/2026		S(1)		1,379	D	$42.785(3)	55,639(2)	D
Common Stock	06/17/2026		S(1)		3,401	D	$43.8634(4)	52,238(2)	D
Common Stock	06/17/2026		S(1)		1,238	D	$44.7475(5)	51,000(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.48	06/17/2026		M(1)			6,018	(6)	08/02/2031	Common Stock	6,018	$0	86,038	D

Explanation of Responses:

1. The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026.

2. Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

3. This transaction was executed in multiple trades at prices ranging from $42.295 to $43.27. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

4. This transaction was executed in multiple trades at prices ranging from $43.3342 to $44.3142. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

5. This transaction was executed in multiple trades at prices ranging from $44.3548 to $44.945. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

6. All of the shares subject to this option are fully vested and exercisable as of the date hereof.

	/s/ Benjamin Hohl	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)